US to add warning about heart inflammation to Pfizer, Moderna COVID-19 vaccines


US health authorities plan to update official guidance about administering mRNA Covid vaccines to adolescents and young adults after finding a likely link to rare cases of heart inflammation, but say the overall benefits still “clearly” outweigh the risks. 

The decision was announced during a meeting of experts convened by the Centers for Disease Control and Prevention on Wednesday that reviewed 323 confirmed instances of myocarditis and pericarditis, inflammation of the lining surrounding the heart, among people under 30.

Of these, 309 were hospitalized, 295 were discharged, nine remain hospitalized with two in intensive care, and there is no outcome data for five cases.

The cases are predominantly among males, most occur after the second dose, and there are no confirmed deaths. 

The data is current as of June 11, when more than 50 million doses of both the Pfizer and Moderna mRNA vaccines had been administered to people aged 12-29 in the United States.

While the case numbers are low, they are still higher than what would be expected in these age groups and researchers are studying possible biological triggers.

“Myocarditis is a rare disease but it’s not a new disease, it’s been around for a while,” Matthew Oster, a member of the CDC’s COVID-19 vaccine task force told the meeting, noting that the estimated background rate of myocarditis is about 0.8 per 100,000 children per year.

Oster said the illness was thought to be caused by viruses in some cases, although there could be other triggers.

“It does appear that mRNA vaccine may be a new trigger for myocarditis,” he said.

According to the CDC, for every million second doses given to 12-to-17-year-old boys, 5,700 COVID-19 cases, 215 hospitalisations, 71 ICU admissions and two deaths across 120 days would be prevented by vaccination. 

Between 56 to 69 cases of myocarditis would be expected as a result of the vaccines.

“Currently, the benefits still clearly outweigh the risks for Covid-19 vaccination in adolescents and young adults,” CDC scientists said in a presentation.

The CDC and Food and Drug Administration plans to update their advice and warning labels to reflect the potential risks.

If a person develops pericarditis after their first dose, they should wait until their symptoms clear and consult their doctor before getting a second dose, according to the draft guidance which will soon be finalized.

If a person develops myocarditis after their first dose, they will be advised to defer their second dose until more information is known.

The independent experts attending the virtual meeting largely agreed with the conclusions, though some panelists were more cautious.

If a patient develops pericarditis after their first dose, then “I would be very hesitant to provide a second dose of the messenger RNA vaccine,” said Pablo Sanchez, a professor of pediatrics at Ohio State University and Nationwide Children’s Hospital.

While children are less affected by COVID-19 than adults, the virus has still hospitalized more than 3,000 under-18s in the United States and led to more than 300 deaths, according to official data. Some 2,700 people under 30 have died from Covid.

Messenger RNA vaccines have been proven to be extraordinarily protective against the disease. 

Beyond protecting children from the immediate risks of Covid, pediatricians also want to shield them from possible long-term impacts such as long Covid and a rare but very serious post-viral complication called Multisystem Inflammatory Syndrome in children (MIS-C).

Ahead of the meeting, Monica Gandhi, infectious diseases and public health expert at the University of California San Francisco pointed out that the United States has gone beyond some other countries’ recommendations on vaccinating teens.

These include Germany and Israel, which only recommend vaccinating adolescents who are at high risk, while Britain is still examining the data and hasn’t yet reached a decision.

(AFP)



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *